Boston Scientific (BSX) to Update on Three co-Primary Endpoints for PREVAIL at ACoC

March 6, 2013 4:38 PM EST Send to a Friend
Boston Scientific Corp. (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the 62nd Annual Scientific Sessions of the American College of Cardiology, and will include all three co-primary endpoints that evaluate safety and efficacy of the WATCHMAN® Left Atrial Appendage (LAA) Closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy. This will be the first time all three co-primary endpoints in the PREVAIL study will be presented.

The preliminary results of the PREVAIL Trial will be presented on March 9 in San Francisco, California by David R. Holmes Jr., M.D., Mayo Clinic, Rochester, Minn., at 9:10 a.m. PT, in the Moscone Center, South, Esplanade Ballroom.

Specifically, Dr. Holmes will present preliminary analysis on the following co-primary endpoints:

* Acute (7-day) occurrence of death, ischemic stroke, systemic embolism and procedure or device related complications requiring major cardiovascular or endovascular intervention
* Comparison of composite of stroke, systemic embolism, and cardiovascular/unexplained death at 18 months follow-up
* Comparison of ischemic stroke or systemic embolism occurring from greater than 7 days post randomization to 18 months follow-up


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment